Trial Profile

Phase 1 study of the safety and tolerability of CORT125134.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Relacorilant (Primary)
Indications Cushing syndrome
Focus Adverse reactions

Most Recent Events

28 Apr 2016 Results published in a Corcept Therapeutics media release.
13 Oct 2015 The results of this trial will be presented at the annual meeting of the American Association of Pharmaceutical Scientists, according to a Corcept Therapeutics media release.
12 Mar 2015 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com